ADR Biomedical Holdings Inc. (TYO:3750)

Japan · Delayed Price · Currency is JPY

788.00

+7.00 (0.90%)

Oct 6, 2026, 3:30 PM JST

Market Cap	7.04B -8.7%
Revenue (ttm)	101.00M +13.5%
Net Income	-558.00M
EPS	-62.50
Shares Out	8.93M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,600
Open	778.00
Previous Close	781.00
Day's Range	773.00 - 795.00
52-Week Range	759.00 - 890.00
Beta	0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About ADR Biomedical Holdings

ADR Biomedical Holdings Inc. engages in the research, development, production, and sale of cell therapy related medical devices in Japan. The company sells cell therapy kits, as well as engages in the research and development of cell therapy technology, etc. Its products pipeline includes ECCI-50 for the treatment of male stress urinary incontinence; ECCL-50 to treat liver cirrhosis; and Cyt-006 to prevent postoperative adhesion for primary rectal cancer. The company is also conducting clinical trials/research on cell therapy for a range of dis... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2004

Employees 13

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 3750

Full Company Profile

Financial Performance

In fiscal year 2026, ADR Biomedical Holdings's revenue was 50.00 million, a decrease of -59.02% compared to the previous year's 122.00 million. Losses were -396.00 million, -81.50% less than in 2025.

Financial Statements